These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 1752524)

  • 21. Comparable studies of the behaviour of the plasmic coagulation, the fibrinolysis as well as the platelets under application of dextran or hydroxyethyl-starch (HES).
    Popov-Cenić S; Müller N; Kladetzky RG; Hack G; Lang U
    Bibl Anat; 1977; (16 Pt 2):322-5. PubMed ID: 75005
    [No Abstract]   [Full Text] [Related]  

  • 22. In vivo role of factor XII (Hageman factor) in hypercoagulability and fibrinolysis.
    Herold R; Straub PW
    J Lab Clin Med; 1972 Mar; 79(3):397-412. PubMed ID: 5061394
    [No Abstract]   [Full Text] [Related]  

  • 23. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental and clinical pharmacology of pentosan polysulfate.
    Maffrand JP; Herbert JM; Bernat A; Defreyn G; Delebassee D; Savi P; Pinot JJ; Sampol J
    Semin Thromb Hemost; 1991; 17 Suppl 2():186-98. PubMed ID: 1719639
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of activation of the fibrinolytic mechanism on experimental platelet-rich thrombi in rabbits.
    Hirsh J; Buchanan M; Glynn MF; Mustard JF
    J Lab Clin Med; 1968 Aug; 72(2):245-55. PubMed ID: 5671200
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
    Stehling F; Weber R; Ozcelik A; Bröcker M; Volbracht L; Diener HC; Busch E
    Neurosci Lett; 2008 Aug; 441(1):39-43. PubMed ID: 18597942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of fibrinolysis. A comparative thrombelastographic study.
    Egeblad K
    Scand J Clin Lab Invest Suppl; 1967; 98():1-69. PubMed ID: 4228724
    [No Abstract]   [Full Text] [Related]  

  • 29. [Thrombolytic action of the enzymatic preparation terrilytin].
    Grinberg GE; Mikhaĭlets GA
    Probl Gematol Pereliv Krovi; 1972 Sep; 17(9):21-7. PubMed ID: 4668372
    [No Abstract]   [Full Text] [Related]  

  • 30. Beta-benzal-butyric acid, a new anti-adhesive drug.
    Mannucci PM; Maggi CA; Gioventu M; Marchi E; Terruzzi AB
    Acta Univ Carol Med Monogr; 1972; 53():409-12. PubMed ID: 4670746
    [No Abstract]   [Full Text] [Related]  

  • 31. [Antithrombotic agents, pharmacologic principles].
    Markwardt F
    Z Arztl Fortbild (Jena); 1986; 80(14):565-70. PubMed ID: 3765695
    [No Abstract]   [Full Text] [Related]  

  • 32. [Blood coagulation state and the dynamic function of the thrombocytes in myocardial infarct in the process of heparin therapy].
    Kesler VM
    Zdravookhr Kirg; 1978; (3):8-11. PubMed ID: 27045
    [No Abstract]   [Full Text] [Related]  

  • 33. [Ischemic ictus during thrombolytic treatment in acute myocardial infarct].
    Seijo-Martínez M; Pais A; Castro del Río M; Silva-Martínez M
    Rev Neurol; 2000 Oct 16-31; 31(8):798-9. PubMed ID: 11082894
    [No Abstract]   [Full Text] [Related]  

  • 34. Experimental and clinical studies on the thrombin-like enzyme from the venom of Bothrops atrox. On the primary structure of fragment E.
    Egberg N
    Acta Physiol Scand Suppl; 1973; 400():1-47. PubMed ID: 4599946
    [No Abstract]   [Full Text] [Related]  

  • 35. [Thrombolytic and pharmacodynamic properties of Aspergillus ochraceus protease].
    Klöcking HP; Markwardt F
    Farmakol Toksikol; 1975; 38(3):341-9. PubMed ID: 1084284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thrombolytic properties of the heparin-tissue plasminogen activator complex and its effect on the fibrinolytic and coagulating systems of the blood in animals].
    Shimonaeva EE; Andreenko GV
    Vopr Med Khim; 1988; 34(1):59-62. PubMed ID: 3130724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Urokinase "Green Cross", a new urokinase preparation. II. In vivo studies].
    Fischer M; Pilgerstorfer HW
    Int Z Klin Pharmakol Ther Toxikol; 1969 Apr; 2(2):142-9. PubMed ID: 4895445
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of chronic administration of lathyrogen (beta-aminopropionitrile) on blood clotting and fibrinolytic system in rabbits.
    Bańkowski E; Worowski K
    Thromb Diath Haemorrh; 1969 Nov; 22(2):372-6. PubMed ID: 5380956
    [No Abstract]   [Full Text] [Related]  

  • 39. Fibrinolytic parameters and hemostatic monitoring: identifying and predicting patients at risk for major hemorrhagic events.
    Tracy RP; Bovill EG
    Am J Cardiol; 1992 Jan; 69(2):52A-59A. PubMed ID: 1729879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology of thrombolytic agents. Implications for therapy of coronary artery thrombosis.
    Marder VJ
    Circulation; 1983 Aug; 68(2 Pt 2):I2-5. PubMed ID: 6683134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.